Preparation and characterization of cisplatin-incorporated gelatin nanocomplex for cancer treatment

Ching Li Tseng, Kai Chiang Yang, Ko Chung Yen, Steven Yueh Hsiu Wu, Feng Huei Lin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To develop a polymer-anticancer drug conjugate accompanied by a reduction of anticipated side effects and therapeutic improvement, we employed gelatin nanoparticles (GPs) as carriers for cisplatin (CDDP). The GPs-cisplatin nanocomplex (GP-Pt) was fabricated by a two-step desolvation process from gelatin type A. The parameters for the optimal GP-Pt preparation were investigated, including temperature, the pH of the gelatin solution, glutaraldehyde (GA) concentration, and the time point for CDDP addition. GP-Pt was characterized by its size, surface charge, morphology, and drug release rate. The chemical and physical properties of GP-Pt have been studied using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), differential thermal analysis (DTA), and thermal gravimetric analysis (TGA). In vivo anticancer effects and reductions in toxicity were evaluated by intratumorally injecting GP-Pt into SCID mice that had been injected with human lung carcinoma cells (A549 cells) as a subcutaneous cancer model. The GP-Pt prepared with gelatin type A solution at pH 2.5 with a 0.4% GA addition achieved the smallest size. The FT-IR assay result showed that GPs conjugated with cisplatin via an ion-exchange of the carboxyl group of the gelatin. In vivo anticancer effects were revealed in that GP-Pt could effectively decrease the tumor size, and mice treated with GP-Pt lived longer than those treated with free CDDP, which indicates reduced toxicity due to cisplatin. The systematic investigation of the synthesis parameters showed that it is possible to prepare GPs with a small size distribution and with the incorporation of high cisplatin. We showed that the GP-Pt nanocomplex was less toxic than the free drug, and that it could effectively reduce the tumor size and toxic effects in mice grafted with A549 cells. The results of this study suggest that GP-Pt could be slowly released to reduce the toxicity of cisplatin, and that it may be used as a potential drug delivery system for chemotherapy.

Original languageEnglish
Pages (from-to)932-937
Number of pages6
JournalCurrent Nanoscience
Volume7
Issue number6
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Oncology
Gelatin
Cisplatin
Nanoparticles
Neoplasms
Toxicity
Fourier transform infrared spectroscopy
Poisons
Tumors
Glutaral
Fourier Transform Infrared Spectroscopy
Chemotherapy
Gravimetric analysis
Differential Thermal Analysis
Pharmaceutical Preparations
Surface charge
Differential thermal analysis
Chemical properties
SCID Mice
Ion Exchange

Keywords

  • Cancer
  • Cisplatin (CDDP)
  • Drug delivery
  • Gelatin nanoparticle (GPs)
  • Ion change

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Preparation and characterization of cisplatin-incorporated gelatin nanocomplex for cancer treatment. / Tseng, Ching Li; Yang, Kai Chiang; Yen, Ko Chung; Wu, Steven Yueh Hsiu; Lin, Feng Huei.

In: Current Nanoscience, Vol. 7, No. 6, 12.2011, p. 932-937.

Research output: Contribution to journalArticle

Tseng, Ching Li ; Yang, Kai Chiang ; Yen, Ko Chung ; Wu, Steven Yueh Hsiu ; Lin, Feng Huei. / Preparation and characterization of cisplatin-incorporated gelatin nanocomplex for cancer treatment. In: Current Nanoscience. 2011 ; Vol. 7, No. 6. pp. 932-937.
@article{cb9f1d36a4be4358b09adfb96b66f15d,
title = "Preparation and characterization of cisplatin-incorporated gelatin nanocomplex for cancer treatment",
abstract = "To develop a polymer-anticancer drug conjugate accompanied by a reduction of anticipated side effects and therapeutic improvement, we employed gelatin nanoparticles (GPs) as carriers for cisplatin (CDDP). The GPs-cisplatin nanocomplex (GP-Pt) was fabricated by a two-step desolvation process from gelatin type A. The parameters for the optimal GP-Pt preparation were investigated, including temperature, the pH of the gelatin solution, glutaraldehyde (GA) concentration, and the time point for CDDP addition. GP-Pt was characterized by its size, surface charge, morphology, and drug release rate. The chemical and physical properties of GP-Pt have been studied using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), differential thermal analysis (DTA), and thermal gravimetric analysis (TGA). In vivo anticancer effects and reductions in toxicity were evaluated by intratumorally injecting GP-Pt into SCID mice that had been injected with human lung carcinoma cells (A549 cells) as a subcutaneous cancer model. The GP-Pt prepared with gelatin type A solution at pH 2.5 with a 0.4{\%} GA addition achieved the smallest size. The FT-IR assay result showed that GPs conjugated with cisplatin via an ion-exchange of the carboxyl group of the gelatin. In vivo anticancer effects were revealed in that GP-Pt could effectively decrease the tumor size, and mice treated with GP-Pt lived longer than those treated with free CDDP, which indicates reduced toxicity due to cisplatin. The systematic investigation of the synthesis parameters showed that it is possible to prepare GPs with a small size distribution and with the incorporation of high cisplatin. We showed that the GP-Pt nanocomplex was less toxic than the free drug, and that it could effectively reduce the tumor size and toxic effects in mice grafted with A549 cells. The results of this study suggest that GP-Pt could be slowly released to reduce the toxicity of cisplatin, and that it may be used as a potential drug delivery system for chemotherapy.",
keywords = "Cancer, Cisplatin (CDDP), Drug delivery, Gelatin nanoparticle (GPs), Ion change",
author = "Tseng, {Ching Li} and Yang, {Kai Chiang} and Yen, {Ko Chung} and Wu, {Steven Yueh Hsiu} and Lin, {Feng Huei}",
year = "2011",
month = "12",
doi = "10.2174/157341311798220736",
language = "English",
volume = "7",
pages = "932--937",
journal = "Current Nanoscience",
issn = "1573-4137",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Preparation and characterization of cisplatin-incorporated gelatin nanocomplex for cancer treatment

AU - Tseng, Ching Li

AU - Yang, Kai Chiang

AU - Yen, Ko Chung

AU - Wu, Steven Yueh Hsiu

AU - Lin, Feng Huei

PY - 2011/12

Y1 - 2011/12

N2 - To develop a polymer-anticancer drug conjugate accompanied by a reduction of anticipated side effects and therapeutic improvement, we employed gelatin nanoparticles (GPs) as carriers for cisplatin (CDDP). The GPs-cisplatin nanocomplex (GP-Pt) was fabricated by a two-step desolvation process from gelatin type A. The parameters for the optimal GP-Pt preparation were investigated, including temperature, the pH of the gelatin solution, glutaraldehyde (GA) concentration, and the time point for CDDP addition. GP-Pt was characterized by its size, surface charge, morphology, and drug release rate. The chemical and physical properties of GP-Pt have been studied using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), differential thermal analysis (DTA), and thermal gravimetric analysis (TGA). In vivo anticancer effects and reductions in toxicity were evaluated by intratumorally injecting GP-Pt into SCID mice that had been injected with human lung carcinoma cells (A549 cells) as a subcutaneous cancer model. The GP-Pt prepared with gelatin type A solution at pH 2.5 with a 0.4% GA addition achieved the smallest size. The FT-IR assay result showed that GPs conjugated with cisplatin via an ion-exchange of the carboxyl group of the gelatin. In vivo anticancer effects were revealed in that GP-Pt could effectively decrease the tumor size, and mice treated with GP-Pt lived longer than those treated with free CDDP, which indicates reduced toxicity due to cisplatin. The systematic investigation of the synthesis parameters showed that it is possible to prepare GPs with a small size distribution and with the incorporation of high cisplatin. We showed that the GP-Pt nanocomplex was less toxic than the free drug, and that it could effectively reduce the tumor size and toxic effects in mice grafted with A549 cells. The results of this study suggest that GP-Pt could be slowly released to reduce the toxicity of cisplatin, and that it may be used as a potential drug delivery system for chemotherapy.

AB - To develop a polymer-anticancer drug conjugate accompanied by a reduction of anticipated side effects and therapeutic improvement, we employed gelatin nanoparticles (GPs) as carriers for cisplatin (CDDP). The GPs-cisplatin nanocomplex (GP-Pt) was fabricated by a two-step desolvation process from gelatin type A. The parameters for the optimal GP-Pt preparation were investigated, including temperature, the pH of the gelatin solution, glutaraldehyde (GA) concentration, and the time point for CDDP addition. GP-Pt was characterized by its size, surface charge, morphology, and drug release rate. The chemical and physical properties of GP-Pt have been studied using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), differential thermal analysis (DTA), and thermal gravimetric analysis (TGA). In vivo anticancer effects and reductions in toxicity were evaluated by intratumorally injecting GP-Pt into SCID mice that had been injected with human lung carcinoma cells (A549 cells) as a subcutaneous cancer model. The GP-Pt prepared with gelatin type A solution at pH 2.5 with a 0.4% GA addition achieved the smallest size. The FT-IR assay result showed that GPs conjugated with cisplatin via an ion-exchange of the carboxyl group of the gelatin. In vivo anticancer effects were revealed in that GP-Pt could effectively decrease the tumor size, and mice treated with GP-Pt lived longer than those treated with free CDDP, which indicates reduced toxicity due to cisplatin. The systematic investigation of the synthesis parameters showed that it is possible to prepare GPs with a small size distribution and with the incorporation of high cisplatin. We showed that the GP-Pt nanocomplex was less toxic than the free drug, and that it could effectively reduce the tumor size and toxic effects in mice grafted with A549 cells. The results of this study suggest that GP-Pt could be slowly released to reduce the toxicity of cisplatin, and that it may be used as a potential drug delivery system for chemotherapy.

KW - Cancer

KW - Cisplatin (CDDP)

KW - Drug delivery

KW - Gelatin nanoparticle (GPs)

KW - Ion change

UR - http://www.scopus.com/inward/record.url?scp=82155170694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155170694&partnerID=8YFLogxK

U2 - 10.2174/157341311798220736

DO - 10.2174/157341311798220736

M3 - Article

AN - SCOPUS:82155170694

VL - 7

SP - 932

EP - 937

JO - Current Nanoscience

JF - Current Nanoscience

SN - 1573-4137

IS - 6

ER -